Latest Insider Transactions at Trans Medics Group, Inc. (TMDX)
This section provides a real-time view of insider transactions for Trans Medics Group, Inc. (TMDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TransMedics Group, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TransMedics Group, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Stephen Gordon Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+17.37%
|
$80,000
$16.14 P/Share
|
|
Mar 01
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.97%
|
$600,000
$80.59 P/Share
|
|
Feb 28
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
5,000
-20.18%
|
$400,000
$80.06 P/Share
|
|
Feb 28
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-41.03%
|
$800,000
$80.15 P/Share
|
|
Feb 28
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+29.09%
|
$160,000
$16.14 P/Share
|
|
Feb 28
2023
|
Edwin M Kania Jr |
BUY
Other acquisition or disposition
|
Direct |
242,477
+37.53%
|
$19,155,683
$79.76 P/Share
|
|
Feb 27
2023
|
Edward M Basile |
SELL
Open market or private sale
|
Direct |
5,000
-7.9%
|
$385,000
$77.92 P/Share
|
|
Feb 27
2023
|
David Weill |
SELL
Open market or private sale
|
Direct |
5,934
-19.62%
|
$456,918
$77.08 P/Share
|
|
Feb 27
2023
|
David Weill |
BUY
Exercise of conversion of derivative security
|
Direct |
5,934
+27.14%
|
$83,076
$14.2 P/Share
|
|
Feb 23
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
35,930
-15.68%
|
$2,586,960
$72.84 P/Share
|
|
Feb 23
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,930
+23.91%
|
$574,880
$16.07 P/Share
|
|
Feb 23
2023
|
James R Tobin |
SELL
Open market or private sale
|
Indirect |
10,000
-3.94%
|
$750,000
$75.13 P/Share
|
|
Feb 23
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
37,827
-1.83%
|
$2,723,544
$72.95 P/Share
|
|
Feb 20
2023
|
Stephen Gordon Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,075
+41.03%
|
-
|
|
Feb 20
2023
|
Waleed H Hassanein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,332
+8.05%
|
-
|
|
Feb 20
2023
|
Nicholas Corcoran |
BUY
Grant, award, or other acquisition
|
Direct |
12,886
+50.0%
|
-
|
|
Feb 20
2023
|
Laura Damme VP, Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
5,685
+50.0%
|
-
|
|
Feb 20
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,075
+47.63%
|
-
|
|
Feb 20
2023
|
Miriam Provost VP, Global Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
5,685
+21.43%
|
-
|
|
Feb 14
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,070
-75.79%
|
$284,900
$70.15 P/Share
|
|
Feb 14
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,070
+43.11%
|
$65,120
$16.0 P/Share
|
|
Feb 14
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
2,173
-0.56%
|
$152,110
$70.08 P/Share
|
|
Feb 01
2023
|
John F Carey VP of Operations |
SELL
Open market or private sale
|
Direct |
1,410
-1.88%
|
$88,830
$63.85 P/Share
|
|
Feb 01
2023
|
John F Carey VP of Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,410
+4.2%
|
$38,070
$27.3 P/Share
|
|
Feb 01
2023
|
Stephen Gordon Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-46.67%
|
$310,000
$62.64 P/Share
|
|
Feb 01
2023
|
Stephen Gordon Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.82%
|
$80,000
$16.14 P/Share
|
|
Feb 01
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-1.88%
|
$480,000
$64.21 P/Share
|
|
Jan 23
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
12,362
-1.51%
|
$803,530
$65.74 P/Share
|
|
Jan 23
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,142
-70.73%
|
$204,230
$65.07 P/Share
|
|
Jan 23
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,142
+41.43%
|
$50,272
$16.0 P/Share
|
|
Jan 20
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,558
-81.04%
|
$361,270
$65.21 P/Share
|
|
Jan 20
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,558
+44.76%
|
$88,928
$16.0 P/Share
|
|
Jan 20
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
6,332
-1.52%
|
$411,580
$65.19 P/Share
|
|
Jan 18
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,300
-50.0%
|
$84,500
$65.11 P/Share
|
|
Jan 18
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+33.33%
|
$20,800
$16.0 P/Share
|
|
Jan 18
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
1,306
-0.31%
|
$84,890
$65.09 P/Share
|
|
Jan 17
2023
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-1.76%
|
$480,000
$64.14 P/Share
|
|
Jan 17
2023
|
Stephen Gordon Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-46.67%
|
$300,000
$60.12 P/Share
|
|
Jan 17
2023
|
Stephen Gordon Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.82%
|
$80,000
$16.14 P/Share
|
|
Jan 17
2023
|
John F Carey VP of Operations |
SELL
Open market or private sale
|
Direct |
1,410
-1.88%
|
$87,420
$62.59 P/Share
|
|
Jan 17
2023
|
John F Carey VP of Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,410
+8.32%
|
$53,580
$38.46 P/Share
|
|
Jan 13
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,900
-81.94%
|
$354,000
$60.2 P/Share
|
|
Jan 13
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,900
+45.04%
|
$94,400
$16.0 P/Share
|
|
Jan 03
2023
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,100
-34.81%
|
$250,100
$61.9 P/Share
|
|
Jan 03
2023
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,100
+43.16%
|
$65,600
$16.0 P/Share
|
|
Dec 15
2022
|
Laura Damme VP, Clinical Affairs |
SELL
Open market or private sale
|
Direct |
4,990
-100.0%
|
$294,410
$59.49 P/Share
|
|
Dec 15
2022
|
Laura Damme VP, Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
4,990
+50.0%
|
$189,620
$38.46 P/Share
|
|
Dec 14
2022
|
Laura Damme VP, Clinical Affairs |
SELL
Open market or private sale
|
Direct |
5,947
-100.0%
|
$368,714
$62.43 P/Share
|
|
Dec 14
2022
|
Laura Damme VP, Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
5,947
+50.0%
|
$225,986
$38.46 P/Share
|
|
Dec 13
2022
|
Miriam Provost VP, Global Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
4,315
-11.75%
|
$267,530
$62.62 P/Share
|